NCT06423573View on ClinicalTrials.gov

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

RecruitingOBSERVATIONAL
Enrollment

580

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

November 30, 2031

Study Completion Date

August 1, 2032

Conditions
Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional
Interventions
DRUG

Filsuvez

Topical gel

Trial Locations (5)

Unknown

RECRUITING

CHU de Toulouse, Hôpital Larrey, Toulouse

RECRUITING

Hospital of Skin and Venereal Diseases of Thessaloniki, Thessaloniki

RECRUITING

Hospital Clinic, Barcelona, Barcelona

RECRUITING

Hospital San Juan de Dios (Barcelona), Barcelona

RECRUITING

Guy's and St Thomas' NHS Foundation Trust, London

Sponsors

Lead Sponsor

Amryt Pharma
All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Amryt Pharma

INDUSTRY

NCT06423573 - A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez | Biotech Hunter | Biotech Hunter